<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03094845</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-hdmASIT001</org_study_id>
    <secondary_id>2016-000557-13</secondary_id>
    <nct_id>NCT03094845</nct_id>
  </id_info>
  <brief_title>Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients</brief_title>
  <official_title>Assessment of Safety and Clinical Tolerability of hdmASIT+TM Administered Subcutaneously in House Dust Mite-induced Allergic Rhinoconjunctivitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ASIT Biotech S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ASIT Biotech S.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The
      purpose of this study is to assess the safety and clinical tolerability of subcutaneous
      immunotherapy with hdmASIT+TM in patients with house dust mite-induced allergic
      rhinoconjunctivitis compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2016</start_date>
  <completion_date type="Actual">January 23, 2017</completion_date>
  <primary_completion_date type="Actual">January 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solicited adverse events</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>Local reactions at the injection site
Allergic systemic reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unsolicited adverse events and serious adverse events (SAEs)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations (body systems) and vital signs (heart rate, systolic and diastolic blood pressure)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory investigations (haematology, clinical biochemistry, immunological parameters)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary functions (FEV1) for asthmatic patients</measure>
    <time_frame>up to 7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>House Dust Mite Allergy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>hdmASIT+TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <description>15 injections over 7 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hdmASIT+TM</intervention_name>
    <description>15 injections over 7 weeks</description>
    <arm_group_label>hdmASIT+TM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A medical history of moderate to severe allergic rhinoconjunctivitis for house dust
             mite for at least 12 months (definition of allergy severity according to ARIA
             (Bousquet et al., 2001))

          -  A positive skin prick test to house dust mite Dermatophagoides pteronyssinus

          -  Specific IgE against house dust mite Dermatophagoides pteronyssinus ≥ 0.7 kU/L

          -  Positive response to Conjunctival Provocation Test (CPT)

          -  Being treated with anti-allergic medication for at least 12 months prior to enrollment

          -  For asthmatic patients: confirmed diagnosis of controlled asthma according to Global
             Initiative for Asthma (GINA) guidelines (steps 1-3, GINA 2014), FEV1 ≥ 80% of the
             patient's reference value

        Exclusion Criteria:

          -  Previous immunotherapy with house dust mite allergens within the last 5 years

          -  Ongoing immunotherapy with house dust mite allergens or any other allergens

          -  History of severe systemic reactions and/or anaphylaxis, including to food (e.g.
             peanut, marine animals) or to Hymenoptera venom (e.g. bee, wasp stings) or to
             medication (e.g. penicillin), etc.

          -  Partly controlled or uncontrolled asthma according to GINA guidelines (GINA 2014)

          -  Chronic asthma or emphysema, particularly with a forced expiratory volume in 1 second
             (FEV1) &lt; 80% of the patient's reference value (ECSC)

          -  History of a respiratory tract infection and/or exacerbation of asthma within 4 weeks
             before the screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2017</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

